Dilip Shanghvi

The 2-day Indian Pharma Alliance Conference concluded on Friday and speaking at the conference, Founder and MD of Sun Pharma, Dilip Shanghvi as well as Pankaj Patel of Zydus Cadila say that efforts are underway to meet global quality standards in both products and processes.

US generics business that accounts for nearly half of Sun Pharma sales grew at a moderate pace of 4 percent USD 507 million in the third quarter.

Forbes India has released the annual India rich list and Reliance Industries' Chairman Mukesh Ambani has topped the Forbes' '100 Richest Indians' list with a net worth of USD 22.7 billion.

Over the last year, regulatory hassles have made US market tougher to navigate for Indian companies. Sun Pharmaceutical MD Dilip Shanghvi, however, says this is the time to dig in, and do more to maintain ownership of that market.

The bipartisan support for India from Democratic and Republican Senators was fantastic, said Pepsico-India Holdings Chairman and CEO D Shivakumar, adding, America's innovativeness, start-up and R&D combined with India's entrepreneurship on both product and services has a huge potential for both the countries.

Watch accompanying videos of Antique India Conference 2016, wherein eminent guests like Dilip Shanghvi, MD of Sun Pharmaceutical Industries, Adi Godrej, Chairman of Godrej Group and Sanjay Nayar, CEO of KKR India expressed their views about Budget and economic reforms in India.

With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion

The merger has fortified Sun Pharma‘s position as the world‘s fifth-largest specialty generic pharmaceutical company and the top Indian Pharma company with significant lead in market share.

The ENI Group has requested HOEC board to de-classify it as a promoter. ENI Group will not be part of HOEC's future growth strategy. HOEC will seek Sebi nod on de-classification of promoters.

Dipen Sheth, head of institutional research at HDFC Securities advises investors to buy MCX with a target price of Rs 1180 per share as the MCX business could see a big surprise.

Sajjan Jindal, Chairman & MD, JSW Steel says with iron-ore and mining ordinances, it has become very clear that now it will be through the auction route, through a transparent route. So, I think over the next two years, all these large projects which are mineral based will get sorted out.

The India Business Leader Awards (IBLA) aims to recognize leaders who have made the difference, creating an edge above peers. Watch them celebrate excellence in business leadership for the 10th year.

2014 was a glitzy year for this man. With a net worth of USD 18 billion, 59-year-old Shanghvi became the second richest man in India, out-ranking Lakshmi Mittal on the Forbes India Rich List this year. Sun Pharma, a small start-up in 1983, leapfrogged to become the largest pharma company in India and fifth largest in the world.

Launching a new drug in India, whether a completely new molecule or a generic one, has become a herculean task. The Supreme Court's recent dictat that the government review 157 clinical trials has delayed fresh approvals.

Taro Pharmaceutical and Sun Pharma have mutually agreed to terminate their merger agreement, announced in August 2012, reports CNBC-TV18's Archana Shukla.

Last few months saw some high profile changes in the managements of Indian pharma companies. Entirely promoter-controlled companies giving way to professional managements brought in from top multinationals to drive global ambitions, reports CNBC-TV18's Archana Shukla.

Sun Pharma is in the pink of health and Dilip Shanghvi now wants to repeat the miracle he performed in making Sun Pharma a billion dollar drug maker, with a host of smaller drug companies, reports CNBC-TV18's Archana Shukla.

The Sun Pharma stock rallied 3% today after the drug-maker offered to acquire 100% in the Israeli drug-firm Taro Pharma in which it has 66% stake. While the move got a thumbs-up from analysts, some of Taro’s large shareholders may play spoilsport, reports CNBC-TV18's Archana Shukla.

According to CNBC-TV18's research analyst Ekta Batra it's SPARC which has emerged as the winner from this deal between Sun Pharma and Merck. They are targeting a portfolio of around 12 drugs in around 100 countries but the focus is expected to be the top 10 countries which are expected to contribute around 80% of revenues.